Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
Vor Bio (NASDAQ:VOR) announced that 48-week clinical data from their Phase 3 study of telitacicept in adults with generalized myasthenia gravis will be presented at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. The study, conducted in China and sponsored by Vor's collaborator RemeGen, will be featured as an oral presentation on October 29, 2025, at 10:50am PT at the Hilton San Francisco Union Square.
The presentation will focus on the efficacy and safety results of telitacicept in patients with generalized myasthenia gravis, as part of the Myasthenia Gravis Foundation of America session.
Vor Bio (NASDAQ:VOR) ha annunciato che i dati clinici a 48 settimane del loro studio di fase 3 su telitacicept in adulti con miastenia gravis generalizzata saranno presentati al prossimo American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. Lo studio, condotto in Cina e sponsorizzato dal collaboratore di Vor, RemeGen, sarà presentato oralmente il 29 ottobre 2025 alle 10:50 ora PT presso l'Hilton San Francisco Union Square.
La presentazione si concentrerà sui risultati di efficacia e sicurezza di telitacicept nei pazienti con miastenia gravis generalizzata, come parte della sessione della Myasthenia Gravis Foundation of America.
Vor Bio (NASDAQ:VOR) anunció que los datos clínicos de 48 semanas de su estudio de fase 3 de telitacicept en adultos con miastenia gravis generalizada se presentarán en la próxima American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. El estudio, realizado en China y patrocinado por el colaborador de Vor, RemeGen, se presentará como una intervención oral el 29 de octubre de 2025 a las 10:50 a.m. PT en el Hilton San Francisco Union Square.
La presentación se centrará en los resultados de eficacia y seguridad de telitacicept en pacientes con miastenia gravis generalizada, como parte de la sesión de la Myasthenia Gravis Foundation of America.
Vor Bio (NASDAQ:VOR)는 일반화된 중증근무력증을 가진 성인에서 텔리타시셋(telitacicept) phase 3 연구의 48주 임상 데이터가 다가오는 미국 신경근육 및 전기진단 의학 연차 학회에서 발표될 것이라고 발표했습니다. 이 연구는 중국에서 수행되었으며 Vor의 협력사인 RemeGen이 후원하며, 2025년 10월 29일 PT 오전 10:50에 Hilton San Francisco Union Square에서 구두 발표로 다뤄질 예정입니다.
발표는 일반화된 중증근무력증 환자에서 텔리타시셋의 효능 및 안전성 결과에 초점을 맞추며, 미국 근육질환 재단의 세션의 일부로 다뤄질 것입니다.
Vor Bio (NASDAQ:VOR) a annoncé que les données cliniques sur 48 semaines de leur étude de phase 3 concernant le telitacicept chez des adultes atteints de myasthénie grave généralisée seront présentées lors de la prochaine American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. L’étude, menée en Chine et sponsorisée par le partenaire de Vor, RemeGen, sera présentée oralement le 29 octobre 2025 à 10h50 PT à l’Hilton San Francisco Union Square.
La présentation portera sur l’efficacité et la sécurité du telitacicept chez les patients atteints de myasthenie grave généralisée, dans le cadre de la session de la Myasthenia Gravis Foundation of America.
Vor Bio (NASDAQ:VOR) gab bekannt, dass 48-wöchige klinische Daten aus ihrer Phase-3-Studie zu Telitacicept bei Erwachsenen mit generalisierter Myasthenia gravis auf der kommenden Annual Meeting der American Association of Neuromuscular & Electrodiagnostic Medicine vorgestellt werden. Die in China durchgeführte Studie, die vom Vor-Kooperationspartner RemeGen finanziert wird, wird als mündliche Präsentation am 29. Oktober 2025, 10:50 Uhr PT im Hilton San Francisco Union Square vorgestellt.
Die Präsentation wird sich auf die Wirksamkeits- und Sicherheitsresultate von Telitacicept bei Patienten mit generalisierter Myasthenia gravis konzentrieren, im Rahmen der Sitzung der Myasthenia Gravis Foundation of America.
Vor Bio (NASDAQ:VOR) أعلنت أن بياناتها السريرية لمدة 48 أسبوعاً من دراستها من المرحلة الثالثة لعلاج telitacicept لدى البالغين المصابين بالوهن العضلي الشديد العام ستُعرض في الاجتماع السنوي القادم لـ الجمعية الأمريكية لجمع الأعصاب العضلية والتشخيص الكهربائي. الدراسة، التي أُجريت في الصين وبرعاية شريك Vor، RemeGen، ستُعرض كعرض شفهي في 29 أكتوبر 2025 الساعة 10:50 صباحاً بتوقيت المحيط الهادئ في فندق Hilton San Francisco Union Square.
سيتركز العرض على نتائج الفعالية والسلامة لـ telitacicept لدى مرضى الوهن العضلي الشديد العام، كجزء من جلسة مؤسسة الوهن العضلي الشديد الأمريكية.
Vor Bio（NASDAQ:VOR） 宣布，其针对一般化重症肌无力成人的 telitacicept 第3阶段研究的 48 周临床数据将于即将举行的 美国神经肌肉与电诊断医学年会上发布。该研究在中国开展，由 Vor 的合作伙伴 RemeGen 资助，将作为口头报告于 2025 年 10 月 29 日 10:50 AM（太平洋时间） 在 Hilton San Francisco Union Square 进行展示。
此次报告将重点介绍 telitacicept 在一般化重症肌无力患者中的疗效与安全性结果，作为美国肌无力基金会会议环节的一部分。
- None.
- None.
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, being held October 29 to November 1, 2025, at the Hilton San Francisco Union Square in San Francisco, California.
Oral Presentation Details
Abstract Title: Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study
Session: MGFA (Myasthenia Gravis Foundation of America)
Date & Time: October 29, 2025, at 10:50am PT
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
About Telitacicept
Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a placebo adjusted 4.83-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) at 24 weeks, the primary endpoint of the trial.
Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, South America, and Asia-Pacific to support potential approval in the United States, Europe, and Japan.
About Generalized Myasthenia Gravis
gMG is a rare, chronic autoimmune neuromuscular disorder that disrupts communication between nerves and muscles, leading to muscle weakness that can impact mobility, vision, swallowing, and breathing. The disease is mediated by autoantibodies, most commonly targeting the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), which interfere with neuromuscular transmission. While several therapies are available, many patients continue to experience persistent symptoms or intolerable side effects. As a result, there remains a significant unmet need for new therapies that offer durable efficacy, a favorable safety profile, and convenient administration to improve the quality of life for people living with gMG. There are approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan living with the disease.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
When and where will Vor Bio present its Phase 3 myasthenia gravis study results?
What is the focus of Vor Bio's Phase 3 clinical trial presentation?
Who sponsored the Phase 3 study of telitacicept that Vor Bio will present?
What type of data will be presented at the AANEM meeting for VOR stock?
